Tüdőrák: vizsgálatok itt: Kína
1144 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 2. fázisNot yet taking people in KínaNeoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
- Where
- Xi'an
- Életkor
- 18 év to 75 év
- People
- 178
- Run by
- Tang-Du Hospital
See details and how to joinNCT06475755 - No phaseTaking peopleSRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
- Where
- Lianyungang
- Életkor
- 18 év to 80 év
- People
- 46
- Run by
- The First People's Hospital of Lianyungang
See details and how to joinNCT06476093 - No phaseTaking peopleiCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
- Where
- Guangzhou
- Életkor
- 18 év to 70 év
- People
- 250
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03192501 - 1. fázisTaking peopleGPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03198052 - 1. fázisTaking peopleGPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03198546 - 2/3. fázisTaking peopleTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Where
- Guanzhou
- Életkor
- 18 év and over
- People
- 200
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03755739 - No phaseTaking peopleEvaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 100
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03769129 - 1. fázisTaking peopleTCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
- Where
- Guanzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03778814 - 2. fázisTaking peopleTrametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
- Where
- Guangzhou
- Életkor
- 18 év to 85 év
- People
- 100
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT04803318 - 1. fázisTaking peopleEngineered TILs/CAR-TILs to Treat Advanced Solid Tumors
- Where
- Guangzhou
- Életkor
- 18 év to 85 év
- People
- 40
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT04842812 - Korai 1. fázisTaking peopleStudy of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 11
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT05060796 - 1/2. fázisTaking peopleTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Where
- Guangzhou
- Életkor
- 18 év to 70 év
- People
- 100
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT05187338 - Korai 1. fázisTaking peopleEGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT05341492 - 2. fázisTaking peopleA Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
- Where
- Yichang
- Életkor
- 18 év to 75 év
- People
- 48
- Run by
- Xin-Hua Xu
See details and how to joinNCT06467500 - 4. fázisTaking peopleStudy on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
- Where
- Xi'an
- Életkor
- 18 év and over
- People
- 24
- Run by
- Tang-Du Hospital
See details and how to joinNCT06467786 - 2. fázisTaking peopleDurvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
- Where
- Shijiazhuang
- Életkor
- 18 év to 75 év
- People
- 58
- Run by
- Hebei Medical University Fourth Hospital
See details and how to joinNCT06371482 - 1/2. fázisNot yet taking people in KínaTrametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT06456138 - No phaseNot yet taking people in KínaEfficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 10
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT06453889 - 2. fázisTaking peopleEfficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 760
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT05284539 - 2. fázisTaking peopleEfficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- First Affiliated Hospital of Zhejiang University
See details and how to joinNCT06445881 - 2/3. fázisTaking peopleAnlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 1200
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT04322617 - No phaseTaking peopleChemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 15 000
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT05059951 - 2. fázisTaking peopleEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 220
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT06440954 - 3. fázisTaking peopleSegmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 307
- Run by
- Fudan University
See details and how to joinNCT05717803 - 2. fázisTaking peoplePembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 78
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT05266846